SCHEMBL29327627

SCHEMBL29327627

CS(=O)(=O)c1ccc(C#N)nc1C(=O)Nc1ccc2oc(-c3cccc(Cl)c3)nc2c1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 10/20 0.57
▸ PPARG P37231 2/20 0.51
▸ TP53 P04637 4/20 0.51
▸ THRB P10828 2/20 0.51
▸ PTGS2 P35354 1/20 0.51
▸ BLM P54132 1/20 0.49
▸ TDP1 Q9NUW8 1/20 0.49
▸ LMNA P02545 2/20 0.48
▸ RXFP1 Q9HBX9 2/20 0.46
▸ P2RY14 Q15391 1/20 0.46
▸ PTPN2 P17706 1/20 0.46
▸ PTPN1 P18031 1/20 0.46
▸ MEN1 O00255 1/20 0.45
▸ KMT2A Q03164 1/20 0.45
▸ KDM4E B2RXH2 1/20 0.45
▸ NPC1 O15118 1/20 0.45
▸ ALDH1A1 P00352 1/20 0.45
▸ POLB P06746 1/20 0.45
▸ RAB9A P51151 1/20 0.45
▸ SMN1; SMN2 Q16637 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29327616 0.91 TP53 (0.56) MAPTPPARGTP53THRBPTGS2
SCHEMBL29327620 0.86 TP53 (0.54) MAPTPPARGTP53THRBPTGS2
SCHEMBL29327751 0.85 MAPT (0.55) MAPTPPARGTP53THRBPTGS2
SCHEMBL29327637 0.85 PPARG (0.52) MAPTPPARGTP53THRBLMNA
SCHEMBL29327588 0.85 PPARG (0.59) MAPTPPARGTP53THRBPTGS2
SCHEMBL29327625 0.84 PPARG (0.60) MAPTPPARGTP53THRBRXFP1
SCHEMBL29327624 0.83 MAPT (0.58) MAPTPPARGTP53PTGS2LMNA
SCHEMBL29327628 0.82 MAPT (0.59) MAPTPPARGTP53THRBPTGS2
SCHEMBL29327633 0.82 PPARG (0.54) MAPTPPARGTP53THRBPTGS2
SCHEMBL29327646 0.81 PPARG (0.53) MAPTPPARGTP53THRBRXFP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240239760-A1 PPARG INVERSE AGONISTS AND USES THEREOF FLARE THERAPEUTICS INC. 2024-07-18 — — US disclosed
US-20240239760-A1 PPARG INVERSE AGONISTS AND USES THEREOF FLARE THERAPEUTICS INC. 2024-07-18 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240239760-A1 PPARG INVERSE AGONISTS AND USES THEREOF PPARG, PPARA, PPARD MAPT 4591/4885PPARG 1/4885TP53 1398/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback